Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001628280-25-005480
Filing Date
2025-02-13
Accepted
2025-02-13 17:26:20
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4253
  Complete submission text file 0001628280-25-005480.txt   5685
Mailing Address 1207 17TH AVENUE SUITE 103 NASHVILLE TN 37212
Business Address
KAZIMI A J (Filed by) CIK: 0001075050 (see all company filings)

Type: SCHEDULE 13G

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-85205 | Film No.: 25621773
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)